Lucas Moreno Selected Research

Investigational Therapies (Experimental Therapy)

1/2022	Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study.
12/2020	Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium.
1/2020	Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
1/2020	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
12/2019	Access to Clinical Trials for Adolescents and Young Adults With Cancer: A Meta-Research Analysis.
3/2018	Outcome of children and adolescents with central nervous system tumors in phase I trials.
1/2018	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.
11/2017	Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
9/2017	[Early clinical trials in paediatric oncology in Spain: a nationwide perspective].
8/2017	Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lucas Moreno Research Topics

Disease

34	Neoplasms (Cancer) 01/2022 - 01/2011
23	Neuroblastoma 01/2022 - 01/2011
5	Glioma (Gliomas) 01/2017 - 08/2010
3	Rhabdomyosarcoma 12/2021 - 01/2020
3	Ependymoma 07/2020 - 07/2010
2	Sarcoma (Soft Tissue Sarcoma) 11/2021 - 01/2014
2	Cytokine Release Syndrome 08/2020 - 08/2020
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 12/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Disease Progression 01/2021
1	COVID-19 12/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2020
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2020
1	Hemorrhage 01/2019
1	Breast Neoplasms (Breast Cancer) 01/2018
1	Leukemia 11/2016
1	Thrombocytopenia (Thrombopenia) 01/2015
1	Anemia 01/2015
1	Neutropenia 01/2015
1	Long Term Adverse Effects 07/2013
1	Familial ependymoma 01/2013
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2012
1	Hyperbilirubinemia 01/2012
1	Respiratory Acidosis 01/2011
1	Medulloblastoma 01/2011
1	Asphyxia (Suffocation) 01/2011

Drug/Important Bio-Agent (IBA)

14	Pharmaceutical PreparationsIBA 01/2022 - 01/2011
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2016
3	Biological ProductsIBA 01/2019 - 01/2013
2	Proteins (Proteins, Gene)FDA Link 08/2021 - 04/2016
2	Biological FactorsIBA 01/2021 - 10/2016
2	tocilizumab (atlizumab)FDA Link 08/2020 - 08/2020
2	Aurora Kinase AIBA 01/2020 - 01/2015
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 01/2018
2	Antineoplastic Agents (Antineoplastics)IBA 11/2017 - 01/2011
2	Aurora KinasesIBA 01/2017 - 01/2015
2	Temozolomide (Temodar)FDA LinkGeneric 01/2017 - 11/2011
1	RNA (Ribonucleic Acid)IBA 01/2022
1	ceritinibIBA 12/2021
1	Anaplastic Lymphoma KinaseIBA 12/2021
1	CateninsIBA 11/2021
1	WAY-262611IBA 11/2021
1	Messenger RNA (mRNA)IBA 09/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	Histone Deacetylase InhibitorsIBA 07/2020
1	NucleotidesIBA 07/2020
1	Chimeric Antigen ReceptorsIBA 07/2020
1	MLN 8237IBA 01/2020
1	vistusertibIBA 01/2020
1	ABTL0812IBA 01/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	cediranib (AZD2171)IBA 01/2019
1	Topotecan (Hycamtin)FDA LinkGeneric 01/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2017
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2017
1	Checkpoint Kinase 1IBA 01/2017
1	Vincristine (Oncovin)FDA LinkGeneric 01/2017
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2017
1	N-Myc Proto-Oncogene ProteinIBA 04/2016
1	Oncogene Proteins (Oncogene Protein)IBA 04/2016
1	dipinacoline glutamateIBA 01/2016
1	1- cyclopropyl- 3- (3- (5- morpholin- 4- ylmethyl- 1H- benzoimidazol- 2- yl)- 1H- pyrazol- 4- yl)ureaIBA 01/2015
1	ImidazolinesIBA 01/2014
1	Melphalan (Alkeran)FDA LinkGeneric 07/2013
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2013
1	EndoglinIBA 01/2013
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2012
1	Alanine Transaminase (SGPT)IBA 01/2012
1	Clofarabine (Clolar)FDA Link 01/2012
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2012
1	Sodium Bicarbonate (Baking Soda)FDA LinkGeneric 01/2011

Therapy/Procedure

25	Therapeutics 01/2022 - 01/2011
13	Investigational Therapies (Experimental Therapy) 01/2022 - 01/2015
5	Immunotherapy 01/2022 - 01/2013
3	Combined Modality Therapy 01/2022 - 07/2010
3	Precision Medicine 01/2020 - 01/2019
3	Drug Therapy (Chemotherapy) 01/2019 - 08/2010
3	Induction Chemotherapy 01/2019 - 07/2013
1	Injections 01/2020
1	Oral Administration 01/2020
1	Biological Therapy 01/2015